Free Trial

Neoleukin Therapeutics (NLTX) Competitors

Neoleukin Therapeutics logo
$22.54 +1.07 (+4.98%)
As of 07/16/2025

NLTX vs. PHAR, NUVB, AVBP, ANAB, TRVI, IMTX, MRVI, DAWN, DNA, and STOK

Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Pharming Group (PHAR), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), AnaptysBio (ANAB), Trevi Therapeutics (TRVI), Immatics (IMTX), Maravai LifeSciences (MRVI), Day One Biopharmaceuticals (DAWN), Ginkgo Bioworks (DNA), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

Neoleukin Therapeutics vs. Its Competitors

Neoleukin Therapeutics (NASDAQ:NLTX) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pharming Group has a consensus target price of $30.00, indicating a potential upside of 184.06%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Pharming Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Neoleukin Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -4.14%. Pharming Group's return on equity of -6.01% beat Neoleukin Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neoleukin TherapeuticsN/A -37.22% -30.91%
Pharming Group -4.14%-6.01%-3.23%

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.

In the previous week, Pharming Group had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Pharming Group and 0 mentions for Neoleukin Therapeutics. Pharming Group's average media sentiment score of 0.62 beat Neoleukin Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company Overall Sentiment
Neoleukin Therapeutics Neutral
Pharming Group Positive

Pharming Group has higher revenue and earnings than Neoleukin Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.25
Pharming Group$320.71M2.26-$11.84M-$0.20-52.81

Summary

Pharming Group beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NLTX vs. The Competition

MetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$211.83M$760.92M$5.50B$9.40B
Dividend YieldN/A4.84%4.25%4.09%
P/E Ratio-7.251.4028.1319.86
Price / SalesN/A25.51424.9198.68
Price / CashN/A19.5635.5357.53
Price / Book2.036.728.235.71
Net Income-$57.56M-$4.32M$3.24B$257.80M
7 Day Performance6.02%1.14%0.66%1.12%
1 Month Performance18.82%2.55%8.07%11.30%
1 Year Performance-49.17%-1.89%28.44%16.88%

Neoleukin Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NLTX
Neoleukin Therapeutics
N/A$22.54
+5.0%
N/A-53.1%$211.83MN/A-7.2590
PHAR
Pharming Group
2.0618 of 5 stars
$10.50
+6.2%
$30.00
+185.8%
+16.6%$714.04M$297.20M-52.48280News Coverage
Gap Down
NUVB
Nuvation Bio
3.1432 of 5 stars
$2.07
-0.7%
$7.17
+247.1%
-34.9%$709.78M$7.87M-0.8960
AVBP
ArriVent BioPharma
2.4543 of 5 stars
$20.52
+1.7%
$40.00
+94.9%
+10.5%$701.99MN/A-5.4440
ANAB
AnaptysBio
1.6677 of 5 stars
$23.65
+0.9%
$42.38
+79.2%
-22.1%$694.90M$91.28M-4.88100
TRVI
Trevi Therapeutics
3.8778 of 5 stars
$5.86
-1.6%
$20.88
+256.4%
+131.4%$686.97MN/A-13.0220
IMTX
Immatics
3.1048 of 5 stars
$5.70
+2.8%
$14.67
+157.5%
-51.2%$686.15M$168.65M-33.20260News Coverage
MRVI
Maravai LifeSciences
3.5135 of 5 stars
$2.68
+3.1%
$6.64
+147.7%
-72.6%$682.49M$259.18M-2.35610Positive News
DAWN
Day One Biopharmaceuticals
2.5763 of 5 stars
$6.73
+1.5%
$29.00
+330.8%
-58.7%$682.25M$131.16M-9.4860
DNA
Ginkgo Bioworks
0.7732 of 5 stars
$11.04
-2.8%
$5.77
-47.7%
N/A$650.91M$227.04M-1.21640News Coverage
STOK
Stoke Therapeutics
4.1504 of 5 stars
$11.87
+1.5%
$23.20
+95.5%
-19.3%$650.29M$36.56M15.08100

Related Companies and Tools


This page (NASDAQ:NLTX) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners